Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 355.89M P/E - EPS this Y 43.20% Ern Qtrly Grth -
Income -29.25M Forward P/E - EPS next Y -135.10% 50D Avg Chg 1.00%
Sales 2M PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -3.00%
Recommedations 2.00 Quick Ratio 29.05 Shares Outstanding 30.67M 52W Low Chg 9.00%
Insider Own 14.11% ROA -21.54% Shares Float 16.20M Beta -
Inst Own 70.10% ROE -29.32% Shares Shorted/Prior 2.07M/1.81M Price 16.05
Gross Margin 100.00% Profit Margin - Avg. Volume 89,276 Target Price 32.60
Oper. Margin -1,813.75% Earnings Date - Volume 57,395 Change 0.25%
About Sagimet Biosciences Inc. - Seri

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc. - Seri News
10/16/24 Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
10/11/24 Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
10/01/24 Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
09/30/24 Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/12/24 Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
09/04/24 Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
08/14/24 Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
08/01/24 Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
10:20 AM Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
06/10/24 Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
06/06/24 Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
05/16/24 Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
05/15/24 Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
05/07/24 Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
05/06/24 Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
04/22/24 Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
03/27/24 Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
03/25/24 Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
03/25/24 Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
01/25/24 Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
SGMT Chatroom

User Image drtwits354 Posted - 8 hours ago

$SGMT something’s brewing

User Image Wontstopcantstop Posted - 9 hours ago

$SGMT Close over $6. LFG!

User Image cats44ever Posted - 10 hours ago

$SGMT Maybe a Cantor Fitz ATM day...

User Image Stocks4thought Posted - 11 hours ago

$ELDN Should do me for $.35 gain, ot $SGMT $VKTX $SLNO $BWAY

User Image nastento Posted - 11 hours ago

$SGMT yeah MM are just playing with us. Slow grind up and elevator down. Someone's loading and wants to buy everything under 6 clearly

User Image _www_larval_com_ Posted - 11 hours ago

$SGMT has reverted -5% lower to 2% (~791Kv) in the last few minutes, 11/15 options, follow for more volatility.

User Image nastento Posted - 12 hours ago

$SGMT sitting at resistance. Break and hold 6, pretty much clear skies to close the gap at 8

User Image Jiggitus23 Posted - 12 hours ago

$SGMT

User Image Peterson28 Posted - 13 hours ago

$SGMT Another half million block. Smelling sth is going on.

User Image nastento Posted - 13 hours ago

$SGMT almost $700k at the bid at 5.80

User Image nastento Posted - 13 hours ago

$SGMT financing news?? Lots of buying

User Image Peterson28 Posted - 13 hours ago

$SGMT Take it easy. No one knows anything here. And don’t trust anyone here too. Just a random BS to pump my position. 😂

User Image Peterson28 Posted - 13 hours ago

$SGMT someone is gonna drop a M&A rumor with a $35 offer in the middle of market open.

User Image nastento Posted - 13 hours ago

$SGMT someone dropped a mill today at market

User Image Wontstopcantstop Posted - 14 hours ago

$SGMT

User Image dnpro Posted - 15 hours ago

$SGMT the target price by 2 analyst is $32 and $67 by another specialist. Could be interesting the action here for next months 🎯 Also for $BCAB the TP is $13 that also includes big Buying from Dr. Michael Burry $XBI $SPY

User Image Peterson28 Posted - 1 day ago

$SGMT this will get acquired for $35

User Image Jacovanrensburg Posted - 3 days ago

$SGMT you will see they will go up to $8 in November and maybe more $11 in December-January

User Image Mikelonggggggggg Posted - 3 days ago

$SGMT I need an entry point here

User Image Sergiy79 Posted - 3 days ago

$SGMT Stop loss hunting is a good sign)

User Image nastento Posted - 3 days ago

$SGMT sub 5 today. A pullback was need. Took some profits but leaving half for the run up for phase 3 final design, phase 3 enrollment and financing

User Image Stocks4thought Posted - 4 days ago

$SGMT Compare to $MDGL $VKTX so undervalued.

User Image Stocks4thought Posted - 4 days ago

$SGMT Bold prediction- over $6 today

User Image nastento Posted - 5 days ago

$SGMT typical staircase up and elevator down. Wake me up with financing news

User Image Stocks4thought Posted - 5 days ago

$PRQR $SGMT should be $8 soon

User Image Expharmaguy Posted - 5 days ago

$SGMT Dr. Loomba, a internationally recognized Hepatolgist will present the AI digital patholgy results from SGMT's phase 2 b trial in an oral presentation on Nov 17 at the AASLD(largest liver meeting annually). Why is this significant. Simply put, Histological assessment of MASH fibrosis has certain limitations which make drug assessment challenging. A.I. digital pathology reduces inter-rater variability, and is more sensitive and results of patient responses to the drug, more reproducible. This, the Orphan Drug status, plus the Lancet publication are motivating the increase in share price. Now all we need in the short term is for their Phase 3 to open to enrollment

User Image Himel92 Posted - 5 days ago

The Last month Performance for $SGMT Opening Price: $3.78 Closing Price: $5.13 Highest Price: $5.49 Lowest Price: $2.66 Percentage Change: 35.71% Latest update on my favorite stock. https://www.globenewswire.com/news-release/2024/10/16/2964062/0/en/AITX-Announces-Continuation-of-Exponential-Growth-in-Q2-FY-2025-Financial-Results.html

User Image Peterson28 Posted - 5 days ago

$SGMT Thanks for giving us the exit liquidity.

User Image G101SPM Posted - 5 days ago

@atlantic1 $SGMT $5.71 bid. DAC $4.56 (6.6.24). EXIT $18.00. Thanks for the input on the trade. Since our platform is based on a specific AI algorithm we are governed by a matrix SPM tag format. At the moment the SPM 87.26 tag suggests a long-term EXIT at $18.00. If a material change is recorded, we will pass it along as part of our protocol.

User Image G101SPM Posted - 5 days ago

@atlantic1 $SGMT $5.71 bid. DAC $4.56 (6.6.24). EXIT $18.00. Thanks for the input on the trade. Since our platform is based an a specific AI algorithm we are governed by a matrix SPM tag format. At the moment the SPM 87.26 tag suggests a long term EXIT at $18.00. If a material change is recorded we will pass it along as part of our protocol.

Analyst Ratings
HC Wainwright & Co. Buy Oct 2, 24
JMP Securities Market Outperform Aug 15, 24
HC Wainwright & Co. Buy Aug 15, 24
Goldman Sachs Neutral Jul 1, 24
HC Wainwright & Co. Buy Jun 14, 24
JMP Securities Market Outperform Jun 7, 24
HC Wainwright & Co. Buy Jun 7, 24
JMP Securities Market Outperform May 24, 24
HC Wainwright & Co. Buy May 24, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Happel David President & CEO President & CEO Nov 16 Buy 2.35 590 1,386 590 11/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Sell 16 662 10,592 3,820,275 07/20/23
NEW ENTERPRISE ASSOCIATES 13 L... 10% Owner 10% Owner Jul 18 Buy 16 30,000 480,000 3,850,275 07/20/23